No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVO240628C133000
- 10.42
- -1.73-14.24%
15min DelayClose Jun 28 16:00 ET
11.17High10.31Low
11.17Open12.15Pre Close13 Volume212 Open Interest133.00Strike Price13.67KTurnover1141.16%IV0.48%PremiumJun 28, 2024Expiry Date9.74Intrinsic Value100Multiplier-1DDays to Expiry0.68Extrinsic Value100Contract SizeAmericanOptions Type0.8548Delta0.0231Gamma13.59Leverage Ratio-83.8957Theta0.0000Rho11.62Eff Leverage0.0020Vega
Intraday
- 5D
- Daily
News
The Top Country With Most Scientists per Capita in the World
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
Novo Nordisk Fully Valued Amid Limited Longer-Term Visibility -- Market Talk
"Muscle gain and fat loss" becomes a new trend in the tens of billions of weight loss market, attracting attention with the cooperation between Kalbe Pharma-B (02105) and Novo Nordisk on muscle gain and fat loss research.
With the mutual efforts with Novo-Nordisk, Laike Pharmaceutical is expected to become a frontrunner in the global weight loss market worth hundreds of billions, and achieve a leap in its own valuation in the future.
Top Gap Ups and Downs on Thursday: MU, SONY, ZTS and More
Comments
The first half of 2024 has been a consistently profitable period for my investments, largely driven by my disciplined and strategic responses to earnings reports and news ![]()
. And by carefully analyzing financial statements and market sentiment, I have been able to profit significantly from selling options and employing strangle strategies. Additionally, buying stocks ahead of anticipated positive news and earnings reports has proven to be highly effective! ...
+4
31
14
$Novo-Nordisk A/S(NVO.US$ said it decided to stop its CLARION-CKD phase 3 trial and will book an impairment loss of 5.7 billion Danish kroner ($820 million) in the second quarter after the clinical study failed to meet its primary goal.
The phase 3 CLARION-CKD trial, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease, was conducted by KBP Biosciences, a company acqu...
The phase 3 CLARION-CKD trial, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease, was conducted by KBP Biosciences, a company acqu...
11
Tech stocks supported $S&P 500 Index(.SPX.US$ and $Nasdaq Composite Index(.IXIC.US$ , halting their three-day losing streak, while $Dow Jones Industrial Average(.DJI.US$ ended its five-day rally. $NVIDIA(NVDA.US$rebounded sharply by 6.8%, erasing Monday's losses and pushing its market value back above $3 trillion. $Alphabet-C(GOOG.US$ and $Microsoft(MSFT.US$ both reached record closing highs. Optimistic earnings outlooks helped $FedEx(FDX.US$ shares surge as much as 17% after h...
3
Read more
Art of Trading RA : Very good, well done
, lots to understand from your trades.
约翰の理财库OP Art of Trading RA: Thank you
I love birds 约翰の理财库OP: hello bro , do you think this is a good idea ?
I love birds : btw congratulations for your 88k profit
约翰の理财库OP I love birds: Money market offer a safe and stable investment option for money you may need to access in the short term(not for long term) but liquidable T+0 day
View more comments...